• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙咪嗪在东方人群中的代谢处置:与美托洛尔α-羟化及S-美芬妥英4'-羟化表型的关系。

Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.

作者信息

Koyama E, Sohn D R, Shin S G, Chiba K, Shin J G, Kim Y H, Echizen H, Ishizaki T

机构信息

Department of Clinical Pharmacology, International Medical Center of Japan, Tokyo.

出版信息

J Pharmacol Exp Ther. 1994 Nov;271(2):860-7.

PMID:7965806
Abstract

We studied the metabolic disposition of imipramine by measuring imipramine and its metabolites in plasma and urine simultaneously after a single oral dose of 25 mg of imipramine hydrochloride administered to 16 healthy (three Japanese and 13 Korean) volunteers. Four of the subjects were poor metabolizers (PMs) of metoprolol but extensive metabolizers (EMs) of S-mephenytoin (PMML/EMMP), five subjects were EMs of metoprolol but PMs of S-mephenytoin (EMML/PMMP) and seven subjects were EMs of both metoprolol and S-mephenytoin (EMML/EMMP). The mean (+/- S.D.) oral clearances of imipramine were smaller in the PMML/EMMP group and the EMML/PMMP group than in the EMML/EMMP group, although a statistical difference (P < .05) was found only in the EMML/PMMP vs. the EMML/EMMP group. The mean area under the plasma concentration-time curve (AUC) of desipramine was 9 times greater (P < .01) in PMML/EMMP group, whereas the mean value was 0.6 times smaller (P < .05) in the EMML/PMMP group than in the EMML/EMMP group. The log10 metoprolol/alpha-hydroxymetoprolol ratio correlated positively with the AUC of desipramine (P < .01) and with the AUC ratio of desipramine/imipramine (P < .05) but negatively with the AUC ratio of 2-hydroxyimipramine/imipramine (P < .05). Log10 percent 4'-hydroxymephenytoin excreted in 8-hr urine correlated positively with the AUC of desipramine (P < .01) and with the AUC ratio of desipramine/imipramine (P < .01). The urinary excretions of imipramine and its metabolites also reflected the data derived from plasma samples in the three different phenotype-paired panels.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们对16名健康志愿者(3名日本人及13名韩国人)单次口服25毫克盐酸丙咪嗪后,通过同时测定血浆和尿液中的丙咪嗪及其代谢物,研究了丙咪嗪的代谢情况。其中4名受试者是美托洛尔的慢代谢者(PMs)但S-美芬妥因的快代谢者(PMML/EMMP),5名受试者是美托洛尔的快代谢者但S-美芬妥因的慢代谢者(EMML/PMMP),7名受试者是美托洛尔和S-美芬妥因的快代谢者(EMML/EMMP)。丙咪嗪的平均口服清除率在PMML/EMMP组和EMML/PMMP组中低于EMML/EMMP组,尽管仅在EMML/PMMP组与EMML/EMMP组之间发现有统计学差异(P < 0.05)。去甲丙咪嗪的血浆浓度-时间曲线下平均面积(AUC)在PMML/EMMP组中比EMML/EMMP组大9倍(P < 0.01),而在EMML/PMMP组中均值比EMML/EMMP组小0.6倍(P < 0.05)。log10美托洛尔/α-羟基美托洛尔比值与去甲丙咪嗪的AUC呈正相关(P <

0.01),与去甲丙咪嗪/丙咪嗪的AUC比值呈正相关(P < 0.05),但与2-羟基丙咪嗪/丙咪嗪的AUC比值呈负相关(P < 0.05)。8小时尿液中排泄的4'-羟基美芬妥因百分比的log10与去甲丙咪嗪的AUC呈正相关(P < 0.01),与去甲丙咪嗪/丙咪嗪的AUC比值呈正相关(P < 0.01)。丙咪嗪及其代谢物的尿排泄情况也反映了来自三个不同表型配对组血浆样本的数据。(摘要截断于250字)

相似文献

1
Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.丙咪嗪在东方人群中的代谢处置:与美托洛尔α-羟化及S-美芬妥英4'-羟化表型的关系。
J Pharmacol Exp Ther. 1994 Nov;271(2):860-7.
2
Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.日本抑郁症患者中丙咪嗪和去甲丙咪嗪的稳态血浆浓度与S-美芬妥因4'-羟化状态的关系。
J Clin Psychopharmacol. 1996 Aug;16(4):286-93. doi: 10.1097/00004714-199608000-00003.
3
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.与司巴丁和甲妥英氧化多态性相关的丙咪嗪代谢——一项群体研究。
Br J Clin Pharmacol. 1995 Apr;39(4):433-9. doi: 10.1111/j.1365-2125.1995.tb04473.x.
4
Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
J Pharmacol Exp Ther. 1992 Sep;262(3):1195-202.
5
Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.远东东方人群中美托洛尔和苯妥英氧化多态性:日本人与中国大陆人对比
Clin Pharmacol Ther. 1989 Aug;46(2):198-207. doi: 10.1038/clpt.1989.126.
6
Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.韩国人群中S-美芬妥因羟化缺乏症的发生率及地西泮药代动力学的表型间差异。
Clin Pharmacol Ther. 1992 Aug;52(2):160-9. doi: 10.1038/clpt.1992.125.
7
Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.性别对中国人群中(S)-美芬妥因4'-羟化酶(CYP2C19)活性影响的证据。
Pharmacogenetics. 1997 Apr;7(2):115-9. doi: 10.1097/00008571-199704000-00004.
8
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Clin Pharmacol Ther. 1991 Jan;49(1):18-23. doi: 10.1038/clpt.1991.4.
9
Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.兰索拉唑的代谢情况与S-美芬妥因4'-羟化表型状态的关系。
Clin Pharmacol Ther. 1997 May;61(5):574-82. doi: 10.1016/S0009-9236(97)90137-5.
10
Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.氯米帕明的单剂量动力学:与司巴丁和S-美芬妥因氧化多态性的关系。
Clin Pharmacol Ther. 1994 May;55(5):518-27. doi: 10.1038/clpt.1994.65.

引用本文的文献

1
Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study.慢性疼痛患者面临药物不良反应或对镇痛药无反应时药物代谢酶和转运体的表型及基因型变异评估:一项回顾性研究
J Pers Med. 2020 Oct 27;10(4):198. doi: 10.3390/jpm10040198.
2
Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model.代谢物与母体药物暴露的预测:一种机制性静态模型的推导与应用
Clin Transl Sci. 2020 May;13(3):520-528. doi: 10.1111/cts.12734. Epub 2020 Feb 4.
3
Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity.
CYP2D6 活性缺乏的患者过量服用阿米替林后的长期毒性。
J Med Toxicol. 2011 Sep;7(3):220-3. doi: 10.1007/s13181-011-0158-2.
4
Clinical pharmacokinetics of drugs used to treat urge incontinence.用于治疗急迫性尿失禁药物的临床药代动力学
Clin Pharmacokinet. 2003;42(14):1243-85. doi: 10.2165/00003088-200342140-00004.
5
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.细胞色素P450 2C19基因多态性的临床意义
Clin Pharmacokinet. 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002.
6
Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.奎尼丁对细胞色素P450 2D6的抑制作用及其对西洛他唑代谢的影响。
Clin Pharmacokinet. 1999;37 Suppl 2:41-51. doi: 10.2165/00003088-199937002-00005.
7
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.利用体外和体内数据评估代谢性药代动力学相互作用的可能性。
Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004.
8
The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.选择性5-羟色胺再摄取抑制剂及其代谢产物对人肝微粒体中S-美芬妥英4'-羟化酶活性的影响。
Br J Clin Pharmacol. 1995 Nov;40(5):481-5. doi: 10.1111/j.1365-2125.1995.tb05793.x.